March 7, 2014/Cancer/Research

Research Shows HDL Has Cancer-Fighting Ability

“Good cholesterol” component combats melanoma, lung cancer


It may be time to add ‘potential cancer fighter’ to the list of promising benefits of high density lipoprotein (HDL), the carrier of “good cholesterol,” according to research from Cleveland Clinic’s Lerner Research Institute.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In a series of experiments, Stanley Hazen, MD, PhD, and his team determined that apolipoprotein A1 (apoA1), or the major cardioprotective protein component of HDL, combats metastatic malignant melanoma and lung cancer through multiple pathways. ApoA1 injections not only inhibited tumor growth and progression in experiments with mice, but actually spurred tumor and metastases regression.

Researchers at Cleveland Clinic, including Dr. Hazen; Joseph DiDonato, PhD; Maryam Zamanian-Daryoush, PhD; and Daniel Lindner, MD, PhD, are now poised to translate these findings to therapeutic strategies for the clinical setting.

Similarities between heart disease, cancer

The apoA1 discoveries are a prime example of advances from the evolving field of cardiooncology. “Cardiovascular disease and cancer are not so disparate in the sense that there are major contributing pathways that operate in concert in both diseases,” says Dr. Hazen, Chair of Cellular and Molecular Medicine, the Jan Bleeksma Chair in Vascular Cell Biology and Atherosclerosis, and the Leonard Krieger Chair in Preventive Cardiology. “In apoA1, we may have identified an important central player nexus and a possible intervention that works positively to combat both diseases.”

After in vitro studies ruled out a direct effect of apoA1 on tumor cells, the Cleveland Clinic team determined apoA1 instead modulates innate and adaptive immune systems in the host in multiple ways to create a micro-environment that works against cancer development. For example, they demonstrated apoA1 can switch tumor-associated macrophages from an M2 phenotype to a more beneficial M1; can decrease tumor angiogenesis independent of vascular endothelial growth factor pathways; and can increase levels of tumor-killing CD8 T cells circulating in and around a tumor.


Boosting immune system

Although complexity usually works in cancer’s favor, here it may be a distinct disadvantage.

“The simple elegance of a multipronged approach is that the tumor cell should have a very difficult time in coming up with a solution to negate apoA1 effects,” says Dr. DiDonato, Supervisor of the Cellular and Molecular Medicine Laboratory.

“If apoA1 had a direct effect on the tumor, the tumor could mutate to circumvent apoA1’s direct effect, much like tumors do in response to chemotherapeutic agents that target a single pathway or protein in the tumor cell.” Dr. Hazen says, “In contrast to most chemotherapies, which weaken the immune system and have infection risk as a side effect, apoA1 therapy for these tumors augments the immune system’s functions, harnessing the body’s natural tumor-fighting potential to promote tumor and metastases regression. It’s exciting.”

The investigators observed zero to very limited metastatic melanoma tumor growth in transgenic animals overexpressing apoA1 at approximately twice the normal circulating levels. In further experiments, Dr. Hazen, Dr. DiDonato and their colleagues found palpable tumors regressed 50 percent from their peak volume within one week among animals injected with apoA1, a beneficial result maintained over time.


It remains unknown if apoA1’s anti-inflammatory action is the shared underlying etiology between the benefits of HDL seen in cardiology and potentially now also observed in oncology. “That is the $64,000 question,” Dr. DiDonato says. “What we do know is that inflammation plays a major role, not only in the initiation or establishment of the tumor, but also in the propagation and migration or metastasis of the tumor cells.”

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 1, 2024/Cancer/Research
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024/Cancer/Research
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023/Cancer/Research
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy